39 research outputs found

    Assessing Arrhythmia Risk in Diabetic and Ischemic-preconditioned Rat Hearts

    Get PDF
    The purpose of this study is to understand the extent of protection against arrhythmia that Streptozotocin (STZ) induced diabetes and ischemic-preconditioning (IPC) on Sprague-Dawley rat hearts subjected to ischemia-reperfusion injury. Hearts were extracted and perfused using the langendorff method with aerated Krebs Henseleit solution. ECG recordings were recoded as the hearts were subjected to 35 minute baseline, 30 minute of no flow (ischemia) followed by 1 hour of reperfusion. The four groups investigated were vehicle control, Streptozotocin (STZ) induced diabetic rats (65mg/kg STZ), ischemic preconditioned hearts (IPC) that were subjected to two 3 minute ischemic intervals followed by 5 and 10 minute reperfusion intervals respectively), and finally diabetic hearts that underwent ischemic preconditioning (STZ+IPC). The time elapsed during ischemia until all ventricular activation stops for control hearts is 7.1±0.8 minutes, while STZ, IPC, and IPC + STZ are 15.5± 3.7, 8.6± 0.9 and 9.9± 1.6 minutes respectively. The STZ group was significantly different from the control group. When the time spent by each heart in the normal sinus rhythm state was analyzed during the 60-minute reperfusion period, control animals maintained normal rhythm for 20.9±9 minutes while STZ, IPC, and IPC + STZ maintained 29.6± 12.4, 31.7± 10.2, and 40.94+ 9.6 minutes respectively. Furthermore, the time spent in ventricular fibrillation (VF) was analyzed, and the IPC+STZ group spent 0.24± 0.2 minutes while control hearts spent 11.28± 9.2 minutes in VF. The data suggests a trend of improved arrhythmia protection when treated with STZ, IPC, or both. The IPC+STZ group is potentially displaying an additive cardioprotective effect

    Tumor-associated antigens in bilateral breast cancer.

    No full text
    The purpose of our present study is to determine whether monoclonal antibodies can define an antigenic phenotype which expresses itself in a concordant fashion in synchronous bilateral breast cancer. The monoclonal antibodies DF.3 and B72.3 were reacted (ABC immunoperoxidase) with formalin-fixed, paraffin-embedded sections of bilateral synchronous breast cancers from 19 patients. MAb DF.3 demonstrated a P less than .01 correlation of right-sided vs left-sided reactivity. This suggested that MAb DF.3 could be used as a biologic marker for synchronous bilateral breast cancer. We hypothesized that the majority of clinically asynchronous breast cancers are really biologically synchronous. We used the immunoperoxidase technique in a similar fashion on bilateral metachronous tumors in 17 patients. DF.3 antigen expression correlated (right to left side) at P less than .01 value. This data, supported by previous information, suggests that the term metachronous breast cancer is a clinically arbitrary definition but that biologically most metachronous cancers may well be synchronous

    Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas.

    No full text
    The monoclonal antibody (MAb) B72.3 recognizes a mucin-like glycoprotein, TAG-72, which has been detected in a spectrum of human carcinomas, but not in the normal tissue counterparts. Using avidin-biotin-peroxidase complex (ABC) immunohistochemical techniques, MAb B72.3 was reacted with formalin-fixed, paraffin-embedded fetal and pediatric tissue sections to determine the extent of expression of the recognized antigen in these tissues. First trimester fetal tissues failed to express detectable antigen. Gastrointestinal epithelia from 13 to 34 weeks gestation demonstrated the most immunoreactivity with B72.3 although bronchial respiratory epithelium of the lung, transitional epithelium from the kidney, Hassall\u27s corpuscles of the thymus, and gonadal tissues from fetuses of both sexes were also reactive. The TAG-72 antigen was not detected in fetal breast, pancreas, liver, spleen, adrenal, or heart. Expression of the TAG-72 antigen in malignancy appears to correlate well with fetal tissue reactivity with B72.3

    A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3.

    No full text
    A retrospective analysis of 25 primary adenocarcinomas of the pancreas, 16 metastatic pancreatic tumors, 8 cases of chronic pancreatitis, and 3 adult normal pancreas was performed to ascertain the reactivity of monoclonal antibody (MAb) B72.3 to malignant and nonneoplastic pancreatic lesions. Formalin-fixed, paraffin-embedded sections of pancreas were evaluated by immunohistochemical techniques (avidin-biotin-peroxidase complex [ABC] method). Twenty-one of 25 malignant primary tumors were reactive, and all 16 metastatic sites expressed the B72.3 antigen. In contrast, all cases of pancreatitis and normal pancreas were either weakly reactive or nonreactive. Ten malignant and two benign pancreatic fine-needle aspirates provided results similar to those seen with fixed tissues. Because MAb B72.3 has selective reactivity for primary and metastatic pancreatic cancer, it may be of value as a diagnostic adjunct in cytologic examination or for radioimmunodetection of regional and/or distant metastases of adenocarcinoma of the pancreas

    A comparison of tumor-related antigens in male and female breast cancer.

    No full text
    A retrospective analysis was undertaken in which 15 female and 15 male breast cancers were matched by age, stage, estrogen receptor status, and histologic type. Our protocol compares male and female breast cancers for reactivity with antibodies against tumor-associated antigens known to be present on female breast cancer cells. Formalin-fixed sections of each primary tumor were reacted in the ABC immunoperoxidase assay against antibodies B72.3 and DF.3 and an antibody to the ras p21 antigen. Reactivity to B72.3 and DF.3 was similar. However, the ras p21 antigen was expressed to a significantly greater extent in female breast cancers (p = .0008). Thus, although there are similarities in antigenic phenotype of male and female breast cancers, some female breast cancers may have a different pathogenesis as demonstrated by increased amounts of a specific oncogene product

    Estrogen receptor determination in fine needle aspirates of the breast. Correlation with histologic grade and comparison with biochemical analysis.

    No full text
    Material obtained by fine needle aspiration (FNA) of 25 surgically removed breast carcinomas was tested for the immunocytochemical localization of estrogen receptor (ER) using the peroxidase-antiperoxidase method and a monoclonal antibody developed against human breast cancer ER. The results were compared to those obtained by the conventional biochemical analysis of cytosol protein. A semiquantitative relationship between the immunoperoxidase stain and the biochemical analysis suggests that cases in which greater than 70% of the cells stain and in which intense staining is present are likely to contain ER in a concentration of greater than 250 fmol/mg of cytosol. Less than 15% stained cells and an absence of intense staining is indicative of a concentration of less than 10 fmol/mg. In only one case was there a significant difference in positivity between the two methods, possibly as a result of a functional heterogeneity of the tumor cell population. Intense staining is strongly suggestive of a tumor of low histologic grade and was never seen in tumors with a high histologic grade or nuclear grade. The immunoperoxidase method of ER detection on material obtained by FNA is a semiquantitative means of selecting patients with breast cancer who are likely to respond to hormonal therapy. The method overcomes many important disadvantages of cytosol analysis and provides clinically significant information regarding the ER content and the degree of tumor differentiation
    corecore